The DOI matches its Crossref record; 23 of the 25 references it cites were found in a registry or an index.
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Open accessAbstract
A main limitation of therapies that selectively target kinase signalling pathways is the emergence of secondary drug resistance. Cetuximab, a monoclonal antibody that binds the extracellular domain of epidermal growth factor receptor (EGFR), is effective in a subset of KRAS wild-type metastatic colorectal cancers. After an initial response, secondary resistance invariably ensues, thereby limiting the clinical benefit of this drug. The molecular bases of secondary resistance to cetuximab in colorectal cancer are poorly understood. Here we show that molecular alterations (in most instances point mutations) of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment in colorectal cancers. Expression of mutant KRAS under the control of its endogenous gene promoter was sufficient to confer cetuximab resistance, but resistant cells remained sensitive to combinatorial inhibition of EGFR and mitogen-activated protein-kinase kinase (MEK). Analysis of metastases from patients who developed resistance to cetuximab or panitumumab showed the emergence of KRAS amplification in one sample and acquisition of secondary KRAS mutations in 60% (6 out of 10) of the cases. KRAS mutant alleles were detectable in the blood of cetuximab-treated patients as early as 10 months before radiographic documentation of disease progression. In summary, the results identify KRAS mutations as frequent drivers of acquired resistance to cetuximab in colorectal cancers, indicate that the emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression and suggest early initiation of a MEK inhibitor as a rational strategy for delaying or reversing drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients who initially respond to anti-EGFR develop acquired resistance within 12 to 18 months due to secondary mutations in KRAS genes, EGFR exodomain alteration, and clonal selection [9].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We and others previously reported that KRAS acquired mutations are responsible for secondary resistance to anti-EGFR therapies in CRC(22, 23).”
From EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. (2020) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“Patients who fail to respond to therapy initially exhibit intrinsic resistance, whereas those who relapse after initial response are associated with acquired resistance [9].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [9]
In the citing paper
“Emergence of KRAS amplification and acquisition of secondary KRAS mutations (G12C, G12D, G13D and Q61H) was detected as one mechanism of acquired resistance in metastatic CRC patients, who relapsed on cetuximab or panitumumab treatment (78, 79).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [78]
In the citing paper
“KRAS point mutations and gene copy number gains are responsible not only for primary but also for acquired resistance in 38–60 % of patients who relapse on cetuximab or panitumumab [37-39].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [38]
In the citing paper
“KRAS alterations could be identified noninvasively 5–10 months before radiographic disease progression by analyzing cell-free circulating tumor DNA (ctDNA) [37, 38].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [38]
In the citing paper
“however, the proof of principle that such an approach could complement tumor biopsy and provide an early warning of acquired resistance has been established [38, 41, 136].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [38]
In the citing paper
“To address these challenges, Mirati Therapeutics conducted high-resolution crystal structure analyses of compounds bound to mutant KRAS proteins, optimizing these compounds to develop MRTX1133, a non-covalent, selective inhibitor for KRAS G12D [60].”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [60]
In the citing paper
“For instance, BRAF (V600E) and MAP2K1/MEK1 (K57T, K57N, I99_K104 deletion, and E102_I103 deletion) can also cause acquired drug resistance [94, 108–111].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [110]
In the citing paper
“By performing repeat biopsies and evaluating circulating tumor DNA, investigators observed the emergence of KRAS mutations as a resistance mechanism (Diaz et al., 2012; Misale et al., 2012).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Misale et al., 2012
In the citing paper
“non-invasive measures such as molecular interrogation of circulating tumor cells or plasma DNA may help capture the heterogeneity of resistance in patients, as was done to identify the development of KRAS mutations in colorectal cancers that acquire resistance to cetuximab (Diaz et al., 2012; Misale et al., 2012).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Misale et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationCirculating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K. E., Goodman, S. N., Li, M., Thornton, K. A., Agrawal, N., Sokoll, L. J., Szabo, S., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,746
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationEGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,095
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Self-citationMolecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Bardelli, A., & Siena, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6116 · Cited by 746
Self-citationActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
Arcila, M. E., Oxnard, G. R., Nafa, K., Riely, G. J., Solomon, S. B., Zakowski, M. F., Kris, M. G., Pao, W., Miller, V. A., & Ladanyi, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2277 · Cited by 574
Cited by
Sorted by citations
Items 901–1,000 of 1,014
Jin, C. E., Yeom, S., Koo, B., Lee, T. Y., Lee, J. H., Shin, Y. M., & Lim, S. (2017) · Oncotarget · doi:10.18632/oncotarget.20038 · Cited by 23
Brammeld, J. S., Petljak, M., Martincorena, I., Williams, S. P., García‐Alonso, L., Dalmases, A., Bellosillo, B., Robles‐Espinoza, C. D., Price, S., Barthorpe, S., et al. (2017) · Genome Research · doi:10.1101/gr.213546.116 · Cited by 23
Stahel, R. A., Bogaerts, J., Ciardiello, F., Ruysscher, D. D., Dubsky, P. C., Ducreux, M. P., Finn, S. P., Laurent‐Puig, P., Peters, S., Piccart, M. J., et al. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.004 · Cited by 22
Fu, S., Liu, X., Luo, M., Xie, K., Nice, E. C., Zhang, H., & Huang, C. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1299006 · Cited by 22
Gabriel, E. M., & Bagaria, S. P. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00297 · Cited by 22
Liquid Biopsy, the hype vs. hope in molecular and clinical oncology
Mohanty, A., Mohanty, S. K., Rout, S., & Pani, C. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.06.002 · Cited by 22
Rhaiem, R., Rached, L. J., Tashkandi, A., Bouché, O., & Kianmanesh, R. (2022) · Cancers · doi:10.3390/cancers14030816 · Cited by 22
Kim, H., Kim, S. Y., Kim, J., Kim, J. E., Hong, Y. S., Han, B., Tak, E., Ryu, Y., Kim, S., & Kim, T. W. (2022) · Scientific Reports · doi:10.1038/s41598-022-05694-x · Cited by 22
Cell-free DNA as a biomarker in cancer
Eibl, R. H., & Schneemann, M. (2022) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2022.20 · Cited by 22
Clonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer
Anupriya, S., Chakraborty, A., & Patnaik, S. (2022) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2022.108445 · Cited by 22
Cremolini, C., Montagut, C. O., Ronga, P., Venturini, F., Yamaguchi, K., Stintzing, S., & Sobrero, A. F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.946850 · Cited by 22
Hu, S., Han, Y., Tan, T.-Y., Chen, H., Gao, J.-W., Wang, L., Yang, M., Zhao, L., Wang, Y., Ding, Y., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.167874 · Cited by 22
Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies
Akkad, J., Bochum, S., & Martens, U. M. (2015) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-015-1276-0 · Cited by 22
Kondo, T., Ozawa, S., Ikoma, T., Xy, Y., Kanamori, K., Suzuki, K., Iwabuchi, H., Maehata, Y., Miyamoto, C., Taguchi, T., et al. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.43 · Cited by 22
Use of Liquid Biopsy in Monitoring Colorectal Cancer Progression Shows Strong Clinical Correlation
Sun, Q., Liu, Y., Liu, B., & Liu, Y. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.09.009 · Cited by 22
López, S. O., Garcı́a-Olmo, D. C., García‐Arranz, M., Peiró‐Pastor, R., Aguado, B., & García‐Olmo, D. (2018) · Cancer Medicine · doi:10.1002/cam4.1399 · Cited by 22
Toor, O. M., Ahmed, Z., Bahaj, W., Boda, U., Cummings, L. S., McNally, M. E., Kennedy, K. F., Pluard, T., Hussain, A., Subramanian, J., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1015 · Cited by 22
Colorectal cancer genomics and designing rational trials
Mondaca, S., & Yaeger, R. D. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.27 · Cited by 22
Self-citationZhu, H., Wang, C., Wang, J., Chen, D., Deng, J., Deng, J., Fan, J., Badakhshi, H., Huang, X., Zhang, L., et al. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.09.18 · Cited by 22
Galbiati, S., Damin, F., Burgio, V., Brisci, A., Soriani, N., Belcastro, B., Resta, C. D., Gianni, L., Chiari, M., Ronzoni, M., et al. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.12.004 · Cited by 22
Graves‐Deal, R., Bogatcheva, G. T., Rehman, S., Lu, Y., Higginbotham, J. N., & Singh, B. (2019) · Oncotarget · doi:10.18632/oncotarget.26663 · Cited by 22
Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management
Lieu, C. H., Corcoran, R. B., & Overman, M. J. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240839 · Cited by 22
Defining subpopulations of differential drug response to reveal novel target populations
Keshava, N., Toh, T. S., Yuan, H., Yang, B., Menden, M. P., & Wang, D. Y. Q. (2019) · npj Systems Biology and Applications · doi:10.1038/s41540-019-0113-4 · Cited by 22
Liquid Biopsy in Solid Malignancy
Scarlotta, M., Şimşek, C., & Kim, A. K. (2019) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2018.0237 · Cited by 22
Liu, J., Xie, L., Cheng, L., Qian, X., Liu, B., Hu, J. Y., Ren, W., & Yang, M. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s86966 · Cited by 21
Shin, S., Chun, S., Kim, T., Kim, Y. J., Choi, H.-J., Jang, S. J., & Kim, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176340 · Cited by 21
Clinical Applications of and Challenges in Single-Cell Analysis of Circulating Tumor Cells
Wu, C.-P., Wu, P. S., Zhao, H., Liu, W., & Li, W. (2017) · DNA and Cell Biology · doi:10.1089/dna.2017.3981 · Cited by 21
Moretto, R., Rossini, D., Capone, I., Boccaccino, A., Perrone, F., Tamborini, E., Masi, G., Antoniotti, C., Marmorino, F., Conca, V., et al. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.07.001 · Cited by 21
Flanagan, D. J., Amirkhah, R., Vincent, D. F., Gündüz, N., Gentaz, P., Cammareri, P., McCooey, A. J., McCorry, A. M. B., Fisher, N. C., Belnoue-Davis, H. L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35134-3 · Cited by 21
Self-citationDichotomous colorectal cancer behaviour
Aljama, S., Lago, E. P., Zafra, O., Sierra, J., Simón, D., Santos, C., Rodríguez-Pascual, J., & Garcia‐Romero, N. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104067 · Cited by 21
Lièvre, A., Artru, P., Guiu, M., Laurent‐Puig, P., Merlin, J., Sabourin, J., Viguier, J., Bastie, A., Seronde, A., & Ducreux, M. P. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.016 · Cited by 21
KRAS Mutant Tumor Subpopulations can Subvert Durable Responses to Personalized Cancer Treatments
Parsons, B. L., & Myers, M. B. (2013) · Personalized Medicine · doi:10.2217/pme.13.1 · Cited by 21
Friedrich, T., Söhn, M., Gutting, T., Janssen, K., Behrens, H., Röcken, C., Ebert, M. P. A., & Burgermeister, E. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.05.003 · Cited by 21
Goto, T., Hirotsu, Y., Amemiya, K., Nakagomi, T., Shikata, D., Yokoyama, Y., Okimoto, K., Oyama, T., Mochizuki, H., & Omata, M. (2017) · Oncotarget · doi:10.18632/oncotarget.19538 · Cited by 21
Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
Pi, C., Zhang, M., Peng, X., Zhang, Y., Xu, C., & Zhou, Q. H. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1395701 · Cited by 21
Chen, D., Gu, K., & Wang, H. (2019) · Cancer Management and Research · doi:10.2147/cmar.s196170 · Cited by 21
Yao, Y., Feng, L., Wang, Z., Chen, H., & Tan, N. (2019) · Biomaterials Science · doi:10.1039/c9bm00905a · Cited by 21
Circulating Tumor DNA as a Novel Biomarker Optimizing Chemotherapy for Colorectal Cancer
Osumi, H., Shinozaki, E., & Yamaguchi, K. (2020) · Cancers · doi:10.3390/cancers12061566 · Cited by 21
Wu, P., Xie, C., Yang, L., Liu, Y., Zeng, J., Li, X., Fang, X., Fan, Y., Zhao, S., Ni, K., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01464-0 · Cited by 21
Shishido, S. N., Masson, R., Xu, L., Welter, L. M., Prabakar, R. K., Souza, A. D., SPICER, D. V., Kang, I. M., Jayachandran, P., Hicks, J. B., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00390-5 · Cited by 21
Moens, L., Falk-Sörqvist, E., Ljungström, V., Mattsson, J. S. M., Sundström, M., Fleur, L. L., Mathot, L., Micke, P., Nilsson, M. F., & Botling, J. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.06.009 · Cited by 21
Schunter, A. J., Yue, X. S., & Hummon, A. B. (2016) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-016-0125-5 · Cited by 21
Feng, Q. F., Gai, F., Sang, Y., Zhang, J., Wang, P., Wang, Y., Liu, B., Lin, D., Yu, Y., & Fang, J. (2018) · Cancer Management and Research · doi:10.2147/cmar.s148134 · Cited by 21
Liquid biopsies to evaluate early therapeutic response in colorectal cancer
Montagut, C. O., Siravegna, G., & Bardelli, A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv228 · Cited by 21
Self-citationMason, J. D., Marks, E., Fan, S., McCormick, K., WILSON, C. G., Harris, A. L., Hamdy, F. C., Cunningham, C., & Goberdhan, D. C. I. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12465 · Cited by 20
Cohen, S. A., Yu, M., Baker, K. K., Redman, M. W., Wu, C., Heinzerling, T. J., Wirtz, R. M., Charalambous, E., Pentheroudakis, G. E., Kotoula, V., et al. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0347-1 · Cited by 20
Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review
Ashouri, K., Wong, A., Mittal, P., Torres‐Gonzalez, L., Lo, J. H., Soni, S., Algaze, S. D., Khoukaz, T., Zhang, W., Yang, Y., et al. (2024) · Cancers · doi:10.3390/cancers16162796 · Cited by 20
Ålgars, A., Avoranta, T., Osterlund, P. J., Lintunen, M., Sundström, J. T. T., Jokilehto, T., Ristimaki, A. P., Ristamäki, R., & Carpén, O. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099590 · Cited by 20
Vilar, E., & Tabernero, J. M. (2012) · Nature · doi:10.1038/486482a · Cited by 20
Trentin, L., Bresolin, S., Giarin, E., Bardini, M., Serafin, V., Accordi, B., Fais, F., Tenca, C., Lorenzo, P. D., Valsecchi, M. G., et al. (2016) · Scientific Reports · doi:10.1038/srep34449 · Cited by 20
Sung, J. S., Chong, H., Kwon, N., Kim, H. M., Lee, J. W., Kim, B., Lee, S. B., Park, C. W., Choi, J. Y., Chang, W. J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22456 · Cited by 20
Russo, M., Lamba, S., Lorenzato, A., Sogari, A., Corti, G., Rospo, G., Mussolin, B., Montone, M., Lazzari, L., Arena, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04506-z · Cited by 20
Self-citationKRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma
Choi, S. M., Andea, A. A., Wang, M., Behdad, A., Shao, L., Zhang, Y., Lu, X., Dittmann, D., Castro, J., Chen, Y.-H., et al. (2018) · Diagnostic Pathology · doi:10.1186/s13000-018-0758-0 · Cited by 20
Mutation-Specific and Common Phosphotyrosine Signatures of KRAS G12D and G13D Alleles
Tahir, R., Renuse, S., Udainiya, S., Madugundu, A. K., Cutler, J. A., Nirujogi, R. S., Na, C. H., Xu, Y., Wu, X., & Pandey, A. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00587 · Cited by 21
CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets
Noorani, I., Bradley, A., & Rosa, J. D. L. (2020) · Genome biology · doi:10.1186/s13059-020-02118-9 · Cited by 20
Haselmann, V., Hedtke, M., & Neumaier, M. (2022) · Diagnostics · doi:10.3390/diagnostics12030748 · Cited by 20
Hotspot mutations in common oncogenes are infrequent in nasopharyngeal carcinoma
Jiang, N., Liu, N., Yang, F., Zhou, Q., CUI, R., Jiang, W., He, Q., Li, W., Guo, Y. Q., Zeng, J., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3376 · Cited by 20
Lee, S., Heinrich, E. L., Lu, J., Lee, W., Choi, A. H., Luu, C., Chung, V. M., Fakih, M., & Kim, J. (2015) · Pancreas · doi:10.1097/mpa.0000000000000379 · Cited by 20
Visualization of tumor heterogeneity by in situ padlock probe technology in colorectal cancer
Heliebi, A. E., Kashofer, K., Fuchs, J., Jahn, S. W., Viertler, C., Matak, A., Sedlmayr, P., & Höefler, G. (2017) · Histochemistry and Cell Biology · doi:10.1007/s00418-017-1557-5 · Cited by 20
Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid BiopsiesPreprint
Russo, M., & Bardelli, A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a029587 · Cited by 20
Self-citationEGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy
Gu, Y., He, H., Qiao, S., Shao, Y., Wang, L., Zhang, Z., Zhang, L., & Zhou, F. (2025) · Advanced Science · doi:10.1002/advs.202505785 · Cited by 19
Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma
Oliveira, R. J. D. S., de Carvalho, A. C., Viana, L. D. S., Carvalho, A. L., & Reis, R. M. (2016) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892811666160309121238 · Cited by 19
Zhou, H., Xiang, Q., Hu, C., Zhang, J., Zhang, Q., & Zhang, R. (2020) · Hereditas · doi:10.1186/s41065-020-00145-x · Cited by 19
Sharma, A., Sinha, S., Rathaur, P., Vora, J., Jha, P. C., Johar, K., Rawal, R., & Shrivastava, N. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10396-7 · Cited by 19
ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer
Akhoundova, D., Hussung, S., Sivakumar, S., Töpfer, A., Rechsteiner, M., Kahraman, A., Arnold, F. M., Angst, F., Britschgi, C., Zoche, M., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34257 · Cited by 19
Osumi, H., Ishizuka, N., Takashima, A., Kumekawa, Y., Nakano, D., Shiozawa, M., Denda, T., Sawada, R., Ouchi, K., Wakatsuki, T., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063071 · Cited by 19
Targeting Asparagine Synthetase in Tumorgenicity Using Patient-Derived Tumor-Initiating Cells
Nishikawa, G., Kawada, K., Hanada, K., Maekawa, H., Itatani, Y., Miyoshi, H., Taketo, M. M., & Obama, K. (2022) · Cells · doi:10.3390/cells11203273 · Cited by 19
Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target
Wang, Y., Zhong, B., Xu, C., Zhan, D., Zhao, S., Wu, H., Liu, M., Lan, X., Cai, D., Ding, Q., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106080 · Cited by 19
Cutshaw, G., Joshi, N., Wen, X., Quam, E., Bogatcheva, G., Hassan, N. A., Uthaman, S., Waite, J. R., Sarkar, S., Singh, B., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202410919 · Cited by 19
Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer
Woo, J., Palmisiano, N. D., Tester, W., & Leighton, J. C. (2013) · Cancer · doi:10.1002/cncr.27994 · Cited by 19
Kato, K., Uchida, J., Kukita, Y., Kumagai, T., Nishino, K., Inoue, T., Kimura, M., Oba, S., & Imamura, F. (2016) · Scientific Reports · doi:10.1038/srep29093 · Cited by 19
Clinical and molecular assessment of regorafenib monotherapy
Kakizawa, N., Suzuki, K., Fukui, T., Takayama, Y., Ichida, K., Muto, Y., Hasegawa, F., Watanabe, F., Kikugawa, R., Tsujinaka, S., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5456 · Cited by 19
Role of circulating tumor DNA in the management of patients with colorectal cancer
Moati, É., Taly, V., Didelot, A., Perkins, G., Blons, H., Taı̈eb, J., Laurent‐Puig, P., & Zaanan, A. (2018) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2018.03.002 · Cited by 19
Bae, S. M., Bae, D., Do, E., Oh, G., Yoo, S. W., Lee, G.-J., Chae, J. S., Yun, Y., Kim, S., Kim, K. H., et al. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.10.006 · Cited by 19
Seo, H., Song, J., Kim, M.-Y., Han, D., Park, H.-J., & Song, M. (2018) · Nutrients · doi:10.3390/nu11010020 · Cited by 19
Calderón-Aparicio, A., Cornejo, A., Orué, A., & Rieber, M. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.890 · Cited by 19
Zhang, L., Hu, D., Tang, B., Cheng, Y., Jiao, C., Cheng, L. Z., Tan, Z., & Zhou, H. (2019) · Disease Markers · doi:10.1155/2019/2829798 · Cited by 19
Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective
Lam, K. K., Wong, S. H., & Cheah, P. Y. (2023) · Cells · doi:10.3390/cells12040631 · Cited by 19
Kim, J., Park, D., Son, D., Nam, S. J., Kim, S. W., Jung, H. H., Kim, Y. J., Park, G., Park, W., Lee, J. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21198 · Cited by 19
Troiani, T., Napolitano, S., Martini, G., Martinelli, E., Cardone, C., Normanno, N., Vitagliano, D., Morgillo, F., Fenizia, F., Lambiase, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0211 · Cited by 18
Huang, Q., Jing, Y., Xiong, L., Li, L., Feng, J., & Cheng, J. G. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06640-x · Cited by 18
Wang, C. Y., Guo, S., Croft, A. J., Yan, X. G., Jin, L., Zhang, X. D., & Jiang, C. C. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22755 · Cited by 18
Chen, C. T., Bartolomeo, M. D., Corallo, S., Strickler, J. H., & Goyal, L. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280871 · Cited by 18
Self-citationMozammel, N., Amini, M. A., Baradaran, B., Mahdavi, S. Z. B., Hosseini, S. S., & Mokhtarzadeh, A. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154290 · Cited by 18
Najim, O., Papadimitriou, K., Broeckx, G., Huizing, M. T., & Tjalma, W. A. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1221773 · Cited by 18
Liquid biopsies reveal the dynamic nature of resistance mechanisms in solid tumors
Meador, C. B., & Lovly, C. M. (2015) · Nature Medicine · doi:10.1038/nm.3899 · Cited by 18
Pathology in drug discovery and development
Jubb, A. M., Koeppen, H., & Reis-Filho, J. S. (2013) · The Journal of Pathology · doi:10.1002/path.4290 · Cited by 18
Intertumoral and Intratumoral Heterogeneity as a Barrier for Effective Treatment of Medulloblastoma
Wang, X., Ramaswamy, V., Remke, M., Mack, S. C., Dubuc, A. M., Northcott, P. A., & Taylor, M. D. (2013) · Neurosurgery · doi:10.1227/01.neu.0000430318.01821.6f · Cited by 18
Lorente, D., Mateo, J., & Bono, J. S. D. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e197 · Cited by 18
Tougeron, D., Cortes, U., Ferru, A., Villalva, C., Silvain, C., Tourani, J. M., Levillain, P., & Karayan, L. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2211-0 · Cited by 18
PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA
Kim, S. T., Lira, M., Deng, S., Lee, S., Park, Y. S., Lim, H. Y., Kang, W. K., Mao, M., Heo, J. S., Kwon, W., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5432 · Cited by 18
Thierry, A. R. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3360-0_1 · Cited by 18
A Practical Approach to Tumor Heterogeneity in Clinical Research and Diagnostics
Stanta, G., & Bonin, S. (2017) · Pathobiology · doi:10.1159/000477813 · Cited by 18
Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors
Ravegnini, G., Sammarini, G., Serrano, C., Nannini, M., Pantaleo, M. A., Hrelia, P., & Angelini, S. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919831902 · Cited by 18
Yang, X., Zhang, K., Zhang, C., Peng, R., & Sun, C. (2019) · BMC Cancer · doi:10.1186/s12885-019-5698-x · Cited by 18
Zhang, M., Wang, H., Li, H., Zhou, Y., Peng, R., Liu, J., & Zhao, Q. (2020) · DNA and Cell Biology · doi:10.1089/dna.2020.5574 · Cited by 18
Saadat, L. V., Boerner, T., Goldman, D. A., Gönen, M., Frankel, T. L., Vakiani, E., Kingham, T. P., Jarnagin, W. R., Wei, A. C.-C., Soares, K. C., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08862-3 · Cited by 18
Self-citationYuan, Y., Liu, Y., Wu, Y., Zhang, J., Shen, C., Zhang, F., Wu, C., & Hu, W. (2021) · The International Journal of Biological Markers · doi:10.1177/17246008211017152 · Cited by 18
Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells
Petti, C., Picco, G., Martelli, M. L., Trisolini, E., Bucci, E. M., Perera, T. P. S., Isella, C., & Médico, E. (2014) · Oncotarget · doi:10.18632/oncotarget.2771 · Cited by 18
Huang, Y., Burns, D. J., Rich, B. E., MacNeil, I. A., Dandapat, A., Soltani, S. M., Myhre, S., Sullivan, B. F., Lange, C. A., Furcht, L. T., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3181-0 · Cited by 18
Metadata
- Authors
- Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., Bencardino, K., Cercek, A., Chen, C.-T., Veronese, S., Zanon, C., Sartore-Bianchi, A., Gambacorta, M., Gallicchio, M., Vakiani, E., Boscaro, V., Medico, E., Weiser, M., Siena, S., Di Nicolantonio, F., Solit, D., & Bardelli, A.
- Affiliations
- Candiolo Cancer Institute (IT)
- Memorial Sloan Kettering Cancer Center (US)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- University of Turin (IT)
- IFOM (IT)
- Corresponding author
- Solit, David
- Bardelli, Alberto
- ORCID
- Venue
- Nature
- Published
- 2012-06
- Volume
- 486
- Issue
- 7404
- Pages
- 532-536
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3927413
- OpenAlex
- W2062109911
- Cited by
- 1,889
- References
- 25
- Citations by year
- 2026: 75 · 2025: 73 · 2024: 81 · 2023: 115 · 2022: 129 · 2021: 138 · 2020: 134 · 2019: 163 · 2018: 161 · 2017: 171 · 2016: 177 · 2015: 163 · 2014: 145 · 2013: 133 · 2012: 28
- FWCI
- 73.66
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Memorial Sloan-Kettering Cancer Center
- European Commission (259015)
- Associazione Italiana per la Ricerca sul Cancro (5 x mille)
- Regione Piemonte
- National Cancer Institute (R01CA127240, P30CA008748, T32CA009207, R25CA020449)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- KRAS mutation, acquired drug resistance, anti-EGFR therapy, cetuximab resistance, colorectal cancer, EGFR, K-ras oncogene, circulating tumor DNA, tumor subclones, MEK inhibition, combination therapy, metastatic colorectal cancer, tumor heterogeneity
- MeSH terms
- Cetuximab, Panitumumab, Alleles, Antibodies, Monoclonal, Humans, Mutation, Promoter Regions, Genetic, Proto-Oncogene Proteins, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Disease Progression, ras Proteins, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
